drugset / Trial / NCT01069003

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003

Phase 4 Completed 2272 enrolled Medtronic Vascular
RandomizedParallel-groupTriple-blindTreatment

Summary

EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.

Timeline

Start
2010-04
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg
Subject Prasugrel Small molecule 5 mg
Subject Prasugrel Small molecule 10 mg
Background Aspirin Small molecule 75 mg
Background Aspirin Small molecule 325 mg